鼠神经生长因子联合丁苯酞序贯治疗急性脑梗死的疗效

Efficacy of Sequential Treatment with Mouse Nerve Growth Factor Combined with Butylphthalide in Acute Cerebral Infarction

目的 探讨鼠神经生长因子联合丁苯酞序贯治疗急性脑梗死的疗效。方法 选取2020年2月至2022年11月商丘市第四人民医院收治的90例急性脑梗死患者,随机分为对照组(n=45)和观察组(n=45)。对照组予以双抗疗法,观察组在对照组用药基础上加用鼠神经生长因子联合丁苯酞序贯治疗。比较两组患者神经缺损程度、日常生活能力、不良反应发生率、临床疗效、血栓状态指标以及炎症反应指标。结果 治疗后,两组患者美国国立卫生研究院卒中量表(NIHSS)评分均降低,且观察组低于对照组,差异均有统计学意义(P <0.05);治疗后,两组日常生活活动能力(ADL)量表Barthel指数均提高,且观察组高于对照组,差异均有统计学意义。观察组治疗有效率(88.89%)高于对照组(66.67%),差异具有统计学意义(P <0.05);治疗后,两组血小板最大聚集率(MPAR),血浆D-二聚体、纤维蛋白原(FIB)水平均降低,且观察组低于对照组,差异均有统计学意义(P <0.05);治疗后,两组患者血清氧化低密度脂蛋白(ox-LDL)、可溶性细胞间粘附分子-1(sICAM-1)均降低,一氧化氮均增高,且观察组ox-LDL、sICAM-1低于对照组,一氧化氮高于对照组,差异均有统计学意义(P <0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论 双抗疗法联合鼠神经生长因子及丁苯酞序贯治疗急性脑梗死疗效确切,可有效改善患者神经缺损症状、血栓状态,降低血清炎症因子水平,且不会增加不良反应。

Objective To investigate the efficacy of sequential treatment with mouse nerve growth factor combined with butylphthalide in acute cerebral infarction.Methods Ninety patients with acute cerebral infarction admitted to The Fourth People’s Hospital of Shangqiu from February 2020 to November 2022 were randomly divided into a control group(n=45)and an observation group(n=45).The control group received dual antiplatelet therapy,while the observation group received mouse nerve growth factor combined with butylphthalide sequential treatment in addition to the control group’s medication.The degree of neurological deficit,activities of daily living,incidence of adverse reactions,clinical efficacy,thrombotic status indicators,and inflammatory response indicators were compared between the two groups.Results After treatment,the National Institutes of Health Stroke Scale(NIHSS)scores of both groups decreased,with the observation group scoring lower than the control group,showing statistically significant differences(P<0.05).After treatment,the Barthel Index of Activities of Daily Living(ADL)in both groups increased,with the observation group scoring higher than the control group,showing statistically significant differences.The effective rate of treatment in the observation group(88.89%)was higher than that in the control group(66.67%),with statistically significant differences(P<0.05).After treatment,the maximum platelet aggregation rate(MPAR),plasma D-dimer,and fibrinogen(FIB)levels in both groups decreased,with the observation group showing lower levels than the control group,with statistically significant differences(P<0.05).After treatment,the serum oxidized low-density lipoprotein(ox-LDL)and soluble intercellular adhesion molecule-1(sICAM-1)levels in both groups decreased,while nitric oxide levels increased,with the observation group showing lower ox-LDL and sICAM-1 levels and higher nitric oxide levels than the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Sequential treatment with dual antiplatelet therapy combined with mouse nerve growth factor and butylphthalide is effective in treating acute cerebral infarction.It can effectively improve neurological deficit symptoms,thrombotic status,and reduce serum inflammatory factor levels without increasing adverse reactions.